Laura Martín Losada
Guadarrama, Madrid, 28440, Spain
NCT Number: NCT04117126
This study evaluates effectiveness to apply prompted voiding in urinary incontinence and dependence patients admitted at functional recovery ward in a mid-stay hospital. This behavioural therapy is recommended in Best Practice Guidelines, and it has good results in elderly living in the community or in nursing home but yet it has not shown his benefits in hospitalized elderly patients for a long time.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
Guadarrama, Madrid, 28440, Spain
The increased level of chronic diseases, greater chances of survival and older people hospitalized, place the Urinary Incontinence (UI) problem in a priority position both in hospital and community care. Guadarrama (Public Madrid Health Service) is a medium-stay Hospital. It makes treatment to recover from acute disease and UI has 80% prevalence at admitted patients.
Main objective:To assess the efficacy of Prompted Voiding (PV) therapy for reverse of UI status in elderly patients hospitalized in a Functional Recovery Ward. (FRW) Methods: Experimental research pre/post-Intervention, with 5 repeated measures data: baseline (preintervention); at discharge, at one, three and six months after discharge (post-intervention). Sample size is 212 admitted patients in the FRW with UI. Prompted voiding intervention will be applied by nursing team following the procedure hospital approved and it will be individualized to each patient.
Main Outcome: urinary continence (YES/NO), others outcomes: amount and frequency of urine loss, type of incontinence pads; follow-up: urinary continence at one, three, and six months after discharge.
Applicability: Incorporating Prompted Voiding Therapy in UI patients care, encouraging global care, relevant implications for reduce the morbidity, improvement the quality of life, decrease health costs.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.
Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.
Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control.
Time frame: at admission, at discharge (about 30 to 60 days), 1 , 3 and 6 month post discharge
To value the efficacy of prompted voiding therapy to recovery urinary continence in elderly hospitalized at functional recovery ward. Data wil be collected from nursing assessment at admission, at discharge and telephone call.
Time frame: at admission, each 15 days along admission, at discharge (about 30 to 60 days).
To value the efficacy of prompted voiding therapy to improve urinary incontinence episodes/symptoms (episodes frequency, volume loss, type pad used) in elderly hospitalized at functional recovery ward. It Will be measure with assistance nurse record.
Time frame: at admission, at discharge.(about 30 to 60 days)
Assessment will be with IU4 questionnaire and NANDA diagnosis. Data will be collected from nursing assessment at admission and nursing assesment at discharge records.
Time frame: at admission, at discharge.(about 30 to 60 days)
Assessment will be with IU4 questionnaire and NANDA diagnosis. Data will be collected from nursing assessment at admission and nursing assesment at discharge records.
Time frame: at admission, at discharge.(about 30 to 60 days)
Assessment will be with IU4 questionnaire and NANDA diagnosis. Data will be collected from nursing assessment at admission and nursing assesment at discharge records.
Time frame: at admission, at discharge.(about 30 to 60 days)
Assessment will be with IU4 questionnaire and NANDA diagnosis. Data will be collected from nursing assessment at admission and nursing assesment at discharge records.
Time frame: at admission, at discharge.(about 30 to 60 days)
Assessment will be with IU4 questionnaire and NANDA diagnosis. Data will be collected from nursing assessment at admission and nursing assesment at discharge records.
Time frame: at admission, at discharge.(about 30 to 60 days)
Assessment will be with IU4 questionnaire and NANDA diagnosis. Data will be collected from nursing assessment at admission and nursing assesment at discharge records.
Time frame: at admission, at discharge (about 30 to 60 days)
To Identify promoting/difficulty continence factors. Data will be collected from clinical history records.
Time frame: at admission, at discharge (about 30 to 60 days)
To Identify promoting/difficulty continence factors. Data will be collected from clinical history records. Cognitive impairments will be measure with Pfeiffer test.
Time frame: at admission, at discharge (about 30 to 60 days)
To Identify promoting/difficulty continence factors. Data will be collected from clinical history records. Functional ability will be measure with Barthel Scale.
Time frame: at admission, at discharge (about 30 to 60 days)
To Identify promoting/difficulty continence factors. Data will be collected from clinical history records. Risk diseases: Diabetes Mellitus, Parkinson Disease, Heart Failure, Obesity, Urinary Tract infection, Nervous System Diseases, Stroke, Abdomen and pelvis surgery.
Time frame: at admission, at discharge (about 30 to 60 days)
To Identify promoting/difficulty continence factors. Data will be collected from clinical history records and drug prescriptions. Risk drugs: Diuretics; sedatives; hypnotics; anticholinergics; amitriptyline; opioid analgesics, cholinesterase inhibitors.
Time frame: at admission, at discharge (about 30 to 60 days)
To Identify promoting/difficulty continence factors. Data will be collected from clinical history records. Body Mass Index greater than or equal to 25
Time frame: at admission, at discharge (about 30 to 60 days)
To Identify promoting/difficulty continence factors. Data will be collected from clinical history records.
Time frame: at admission, at discharge (about 30 to 60 days)
To Identify promoting/difficulty continence factors. Data will be collected from clinical history records. 3 groups will be assigned: Femoral Fractures, stroke, functional disability.
Time frame: at admission, at discharge (about 30 to 60 days)
Data will be collected from clinical history records. It will be valuated with Norton Scale.
Time frame: at admission, at discharge (about 30 to 60 days)
Data will be collected from clinical history records. It will be valuated with Sytratify Scale.
Time frame: at admission, at discharge (about 30 to 60 days)
To Identify promoting/difficulty continence factors. Data will be collected from clinical history records.
Time frame: at admission, at discharge (about 30 to 60 days)
To Identify promoting/difficulty continence factors. Data will be collected from clinical history records.
Guadarrama Hospital
Other
Efficacy of Prompted Voiding Therapy for Reverse the Urinary Incontinence Status in Elderly Patients Hospitalized in a Functional Recovery Ward.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07070063
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Wroclaw, Lower Silesian Voivodeship, Poland
View Trial DetailsNCT07689409
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Izmir, İzmir, Turkey (Türkiye)
View Trial DetailsNCT05443074
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Ribeirão Preto, São Paulo, Brazil
View Trial DetailsNCT05880862
Accidental Falls, Female Urogenital Diseases
Galveston, Texas, United States
View Trial Details